No Data
Jiangsu Aidea Pharmaceutical (688488): Continuous increase in sales of new anti-AIDS drugs, acquisition of Nanda Pharmaceutical to create a second production line.
New anti-AIDS drugs continue to increase steadily, completing the second curve created by Nanda Pharmaceuticals Holdings, maintaining a "buy" rating for Q1-Q3 2024. The company's revenue was 0.299 billion yuan (-0.89% year-on-year, not labeled as year-on-year basis), with new HIV drugs included.
Jiangsu Aidea Pharmaceutical (688488): Rapid Release of HIV Drugs
Event: Recently, the company released the third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 0.299 billion yuan, a year-on-year decrease of -0.89%. Among them, revenue from innovative anti-HIV drugs was 0.134 billion yuan, a year-on-year
Eddy Pharmaceuticals: Eddy Pharmaceuticals Third Quarter 2024 Report
Eddy Pharmaceuticals 2024 Third Quarter Report
Director and Vice President Wang Jun of Jiangsu Aidea Pharmaceutical (688488.SH) completed the shareholding of 0.6921 million shares.
Jiangsu Aidea Pharmaceutical (688488.SH) announced that the director and vice president Wang Jun has cumulatively reduced his shareholding through centralized bidding...
China Accepts Jiangsu Aidea Pharma's New Indication for HIV Medication
No Data
No Data